ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
ADC Therapeutics SA reported a routine insider equity transaction by its Chief Executive Officer and director, Ameet Mallik. On 12/06/2025, 233,146 common shares were withheld by the company at a price of $3.29 per share to cover his tax obligations arising from the vesting of previously granted restricted share units. After this tax-withholding event, Mallik beneficially owns 1,319,101 common shares directly. This type of Form 4 event reflects administrative handling of equity compensation rather than an open‑market purchase or sale.
ADC Therapeutics SA reported an insider equity transaction involving its Chief Medical Officer, Mohamed Zaki. On 12/06/2025, the company withheld 41,068 common shares at a price of $3.29 per share to cover his tax withholding obligations tied to previously granted restricted share units that vested. After this automatic withholding, Zaki beneficially owns 421,820 common shares, held directly. This type of transaction reflects routine share withholding for taxes rather than an open-market sale.
ADC Therapeutics SA's Chief Accounting Officer reported a routine share transaction under Form 4. On 12/06/2025, the officer had 7,140 common shares disposed of at $3.29 per share, coded as an "F" transaction. This represents shares withheld by the company to cover tax obligations related to the vesting of previously granted restricted share units.
After this withholding event, the officer directly beneficially owns 70,757 common shares of ADC Therapeutics SA. The filing reflects administrative tax settlement activity rather than an open-market buy or sell decision.
ADC Therapeutics SA reported an insider transaction by Chief Legal Officer Peter Graham. On 12/06/2025, the company withheld 49,508 common shares at a price of $3.29 per share to cover his tax obligations arising from the vesting of previously granted restricted share units. After this withholding, Graham beneficially owns 359,034 common shares directly. The filing notes that this is a routine tax withholding transaction rather than an open‑market sale, and no derivative securities transactions were reported.
ADC Therapeutics SA's Chief Financial Officer, Jose Carmona, reported a routine share withholding related to equity compensation. On 12/06/2025, the company withheld 53,236 common shares to cover his tax obligations arising from the vesting of previously granted restricted share units. The shares were valued at $3.29 per share for this tax withholding event.
After this transaction, Carmona beneficially owned 488,656 common shares, held directly. The filing is a standard Form 4 disclosure of insider equity activity rather than an open-market purchase or sale.
ADC Therapeutics SA filed Amendment No. 1 to its shelf registration statement as an exhibit-only update to include a new auditor consent from PricewaterhouseCoopers SA. The company states that this amendment does not change any part of the prospectus and consists only of the facing page, an explanatory note, Part II, signatures, the exhibit index and the new exhibit.
The company estimates total offering-related expenses of $71,341.46, including a SEC registration fee of $8,341.46, legal and accounting fees and printing costs. ADC Therapeutics will bear its own registration expenses, while any selling shareholders would be responsible for brokerage commissions or similar charges if they sell shares under the registration. The filing also restates standard Swiss-law based indemnification provisions for directors and officers and includes customary Securities Act undertakings.
ADC Therapeutics SA reported new clinical data from its ongoing LOTIS-7 Phase 1b open-label trial. This study evaluates the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma, a difficult-to-treat blood cancer. As of the November 17, 2025 cutoff date, 49 patients were considered efficacy evaluable, each with at least six months of follow-up from the start of treatment. These updated data help further characterize how this drug combination performs in heavily pretreated lymphoma patients.
ADC Therapeutics (ADCT): Schedule 13G/A—Prosight Management and affiliated reporting persons disclosed beneficial ownership of 7,195,374 common shares, representing 5.8% of the class, with shared voting and dispositive power over those shares and no sole power. The event date is 09/30/2025. The percentage is based on 123,877,111 shares outstanding as of October 31, 2025.
Within the group, Prosight Fund holds 350,415 shares (0.3%) and Prosight Plus Fund holds 1,586,895 shares (1.3%). The filing certifies the securities were not acquired for the purpose of changing or influencing control of the issuer.
ADC Therapeutics SA filed a resale registration allowing selling shareholders to offer up to 14,696,253 common shares from time to time as described under “Plan of Distribution.” The company is not selling any shares under this prospectus and will not receive proceeds from sales by the selling shareholders.
The filing covers shares issued in an October 2025 private placement, specifically 10,850,100 common shares and 3,846,153 common shares issuable upon exercise of pre-funded warrants. If those pre-funded warrants are exercised in cash, the company may receive up to CHF 307,692, earmarked for working capital and general corporate purposes. ADC Therapeutics’ common shares trade on the NYSE under the symbol ADCT.
ADC Therapeutics (ADCT) filed its Q3 2025 10‑Q, reporting continued operating losses alongside completed and planned capital raises. Net revenue was $16.4 million for the quarter, down from $18.5 million a year ago, driven by $15.8 million in product revenue and $0.7 million in royalties. Net loss was $41.0 million, or $0.30 per share. Cash and cash equivalents were $234.7 million at September 30, 2025.
Operating expenses were $47.4 million, including $0.4 million in restructuring costs this quarter and $13.5 million year‑to‑date tied to a June 2025 plan that reduced headcount by about 30% and initiated the UK facility shutdown. Interest expense totaled $13.4 million for the quarter. The balance sheet shows a deferred royalty obligation of $340.2 million and senior secured term loans of $115.2 million, with shareholders’ equity at a deficit of $238.2 million.
The company closed a June 2025 private placement for gross proceeds of $100.0 million (net $93.1 million) by selling 13,031,161 common shares at $3.53 and pre‑funded warrants to purchase 15,734,267 shares at $3.43. A subsequent October 2025 private placement raised $60.0 million gross (net $57.6 million) via 11,250,000 shares at $4.00 and pre‑funded warrants to purchase 3,846,153 shares at $3.90. Earlier in 2025, $5.0 million in license revenue was recognized upon Health Canada’s conditional approval of ZYNLONTA.